NCR3LG1 and acute myeloid leukemia: Next, we wanted to examine NKp30-CD28 CAR TCRKO or NKp30-CD137 CAR TCRKO T cells and their TCR+ counterparts in vivo ideally to primary AML expressing moderate to intermediate B7H6 levels to evaluate therapeutic efficacy under these conditions.